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Circulation: Cardiovascular Interventions
ORIGINAL ARTICLE

Predictors of Left Ventricular Outflow Tract
Obstruction After Transcatheter Mitral Valve
Replacement in Severe Mitral Annular
Calcification: An Analysis of the Transcatheter
Mitral Valve Replacement in Mitral Annular
Calcification Global Registry
Abdallah El Sabbagh, MD; Mohammed Al-Hijji , MD; Dee Dee Wang, MD; Mackram Eleid , MD; Marina Urena, MD;
Dominique Himbert , MD; Tarun Chakravarty, MD; David Holzhey, MD, PhD; Ashish Pershad, MD;
H. Kenith Fang, MD; Mohammed Nejjari , MD; Firas Zahr, MD; Danny Dvir , MD; Muhammad Rizwan Sardar, MD;
Asim N. Cheema, MD, PhD; Sami Alnasser, MD; Vijay Iyer, MD; Georges Kaddissi, MD; John Webb, MD; Raj Makkar, MD;
Alec Vahanian, MD; William O’Neill, MD; Charanjit Rihal, MD; Mayra Guerrero , MD
BACKGROUND: Several studies have evaluated preprocedural imaging predictors of left ventricular outflow tract obstruction
(LVOTO) after transcatheter mitral valve replacement. The patient cohorts in these studies were heterogeneous and included
patients with transcatheter mitral valve replacement in failed bioprostheses, annuloplasty rings, and severe mitral annular
calcification (MAC). The goal of this study was to evaluate predictors of LVOTO specific to patients undergoing valve-in-MAC.
METHODS: This study included patients with severe MAC who underwent valve-in-MAC and had optimal quality
preprocedural multidetector row computed tomography scans eligible for retrospective analysis. Baseline demographic,
echocardiographic, and procedural data on these patients were collected. multidetector row computed tomography
parameters were analyzed for association with LVOTO, defined as increase in mean LVOT gradient by ≥10 mm Hg with
accompanying hemodynamic instability.
RESULTS: Seventy-one patients with optimal preprocedural computed tomography scans were included in this study (mean
age, 72.5±13.5 years), 9 of which developed LVOTO (all female). Baseline mean LVOT area, neo-LVOT area (145.3 versus
270.9 mm2; P=0.006), indexed neo-LVOT area (90.1 versus 157.4; P=0.05), and virtual transcatheter heart valve to septum
distance (3.1 versus 6.9 mm; P=0.002) were lower in the LVOTO group. Expected % LVOT area reduction was higher in the
latter group (58.3 versus 42.7%; P=0.008). In the univariable analysis, the baseline mean LVOT area, neo-LVOT area, indexed
neo-LVOT area, and valve to septum distance were all significantly associated with LVOTO.
CONCLUSIONS: The systolic mean LVOT area, neo-LVOT area, indexed neo-LVOT, expected percentage LVOT area reduction,
and the valve to septum distance were associated with LVOTO after valve-in-MAC.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: calcium ◼ catheter ◼ heart valve ◼ mitral valve ◼ tomography
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WHAT IS KNOWN
• Previous studies evaluating imaging predictors of
left ventricular outflow tract (LVOT) obstruction
after transcatheter mitral valve replacement in mitral
annular calcification have been imprecise and hampered by the heterogeneity of patients included in
the analysis.
• Patients undergoing transcatheter mitral valve
replacement in failed bioprosthetic valves and annuloplasty rings were lumped with patients undergoing valve-in-mitral annular calcification.

WHAT THE STUDY ADDS
• The present study evaluated predictors of LVOT
obstruction specific to patients undergoing valvein-mitral annular calcification.
• The neo-LVOT area, indexed neo-LVOT, and
expected percentage LVOT area reduction were
associated with LVOT obstruction
• The virtual transcatheter heart valve to septum distance was a novel parameter associated with LVOT
obstruction.

Nonstandard Abbreviations and Acronyms
AUC
LVOT
LVOTO
MAC
MDCT
THV
TMVR
ViMAC

S

area under the curve
left ventricular outflow tract
left ventricular outflow tract obstruction
mitral annular calcification
multidetector row computed tomography
transcatheter heart valve
transcatheter mitral valve replacement
valve-in-MAC

evere mitral annular calcification (MAC) is a chronic
degenerative condition that affects the elderly
with comorbidities and presents a therapeutic
challenge to mitral valve replacement.1 Surgical mitral
valve replacement in severe MAC is associated with
high morbidity and mortality, in part due to the highrisk population with comorbidities, along with technical
challenges from the calcium burden.2,3 Transcatheter
mitral valve replacement (TMVR) with a valve-in-MAC
(ViMAC) procedure using a balloon-expandable aortic
transcatheter heart valve (THV) has emerged as a therapeutic option in patients with high surgical risk and
severe MAC.4 Early experience of ViMAC procedures
was obtained through the TMVR in MAC Global registry.4 In that registry, the 30-day mortality was approaching 25%.4 Left ventricular outflow tract obstruction
(LVOTO) was the strongest independent predictor of
mortality, and therefore represents an impactful target
to improve procedural safety.4

LVOTO during TMVR is complex and involves an
intricate interaction of the mitral apparatus, aortic valve,
and the basal septum. Preprocedural ECG-gated multidetector row computed tomography (MDCT) has been
instrumental in planning TMVR in MAC and anticipating
anatomic challenges.5 Data on predictors of LVOTO during TMVR in MAC is limited. Studies thus far have been
hampered due to heterogeneous cohorts of patients.
These studies have grouped TMVR in failed surgical
bioprostheses, annuloplasty rings, and MAC, all into one
cohort of patients, making interpretation of results challenging.6–8 In this analysis from the TMVR in MAC Global
Registry, the predictors of LVOTO specific to patients
with severe MAC who underwent TMVR were evaluated.

METHODS
This study was a subgroup analysis of the TMVR in MAC Global
Registry. The study was approved by the Mayo Clinic Institutional
Review Board, and patient consent was waived. The authors
declare that all the supporting data is available within the article. This international multicenter registry included patients at
high surgical risk who underwent TMVR in severe MAC using
balloon-expandable aortic THVs. One hundred sixteen patients
from 51 centers in 11 countries from North America, Europe,
and South America were included in this registry between
September 2012 and March 2017.
Inclusion criteria were adult patients (>18 years), with
symptomatic severe mitral valve disease and severe MAC
deemed to be high risk for conventional surgical mitral valve
replacement by the heart team at their respective institutions.
In the current analysis, patients in whom an MDCT, performed
for purposes of preprocedural planning, was of adequate
quality were eligible for the retrospective analysis. Severe
MAC during enrollment phase was defined as presence of
diffuse, nearly circumferential calcification of the mitral annulus as seen on preprocedural MDCT (Figure 1). MAC severity
was classified using the CT MAC score developed in this registry.9 Data was collected retrospectively using a standardized
case-report form. Baseline demographics, echocardiographic
characteristics were extracted from the case-report forms.
Preprocedural MDCT images were acquired for centralized retrospective analysis of different parameters using
3Mensio Structural Heart Mitral Workflow version 8.1 (Pie
Medical Imaging, Maastricht, the Netherlands). Procedural
data acquired included THV type and size and valve delivery
approach. All procedures were done according to local guidelines with standard techniques via transseptal and transapical
routes. For this analysis, patients who underwent transatrial
TMVR were excluded as anterior mitral leaflets were resected
in these patients to decrease risk of LVOTO. None of the
patients in this study underwent preemptive measures to
mitigate LVOTO risk, such as alcohol septal ablation or electrosurgical anterior leaflet laceration because those were
developed after this registry was initiated. One patient with
predominantly posterior MAC with atypical extensive extension of the calcification into the posterior left ventricular wall
and neo-LVOT area of 317 mm2 developed LVOTO, likely from
the THV being pushed anteriorly by the posterior calcium and
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Figure 1. Preprocedural cardiac multidetector computed tomographic parameters to evaluate predictors of left ventricular
outflow tract (LVOT) obstruction after transcatheter mitral valve replacement in mitral annular calcification (MAC) using
3Mensio Structural Heart Workflow (version 8.1, Pie Medical Imaging, Maastricht, the Netherlands).
VTS indicates virtual transcatheter heart valve to septum distance.

was excluded from the analysis given the unusual mechanism of LVOTO. Postprocedural echocardiographic findings
were recorded. LVOT gradient was measured in a standard
fashion, as recommended by the guidelines,10 using continuous-wave Doppler. LVOT gradient was measured on preoperative and postoperative transthoracic echocardiography,
as well as intraoperative transesophageal echocardiography.
Procedural and in-hospital outcomes and complications were
collected. Patients were grouped into those with versus without development of LVOTO.

Definition of LVOT Obstruction With
Hemodynamic Compromise
For purposes of this analysis, LVOTO with hemodynamic compromise was defined as increase in mean LVOT gradient by ≥10
mm Hg with accompanying hemodynamic instability requiring
treatment with intravenous medications, mechanical support, or
additional cardiac procedures.4,11 Hemodynamic instability data
were extracted from patient charts including intraprocedural
and postprocedural records, depending on when hemodynamic
instability occurred.

Mitral Valve and LVOT MDCT Analysis
Preprocedural MDCT images were obtained from different
centers. Protocols for acquiring the MDCT were according
to standard practice of each center. Images were reviewed
for quality check, including image quality, sufficient number
of slices, contrast use, and gated electrocardiography-synchronization. MDCT images were postprocessed retrospectively at Mayo Clinic using 3Mensio Structural Heart Mitral
Workflow version 8.1 (Pie Medical Imaging, Maastricht, the

Netherlands). Mitral annulus dimensions and LVOT area were
measured using previously described methods (Figure 1).12–
14
Aortomitral angle was determined by measuring the interior angle of the intersection between lines drawn across the
aortic and mitral annulus plane during systole. Neo-LVOT
was measured using a virtual valve embedded in the segmented MDCT in systole at an 80% ventricular/20% atrial
position, in relation to the mitral annular plane. The size of
the virtual valve was chosen according to the manufacturer’s
recommendation for transcatheter aortic valve replacement
based on mitral annular area. The distance from ventricular
edge of the virtual valve frame to the basal interventricular
septum at 80/20 position was measured in systole (virtual
THV to septum distance [VTS]). The percentage of LVOT area
reduction was calculated (Native LVOT area–neo-LVOT area/
native LVOT area). The cross-sectional planimetry of the neoLVOT is then traced during systole and then indexed to body
surface area. The length of the anterior mitral valve leaflet
was measured in the 3-chamber view in diastole. End-systolic
maximal septal thickness as well as septal thickness 10 to
15 mm below the aortic annulus were measured.

Statistical Analysis
Continuous variables are presented as mean±SD or median
(interquartile range) and were compared using a 2-sample t
test for normally distributed variables or the Kruskal-Wallis test
for non-normal variables. Categorical variables are presented
as frequency and percentage and were compared using the χ2
test. Univariate analysis was used to determine significant risk
factors contributing to LVOTO. Receiver-operating characteristics curves were plotted, and the optimal cutoff values of the
predictors of LVOTO were selected as the point that maximized
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Youden J statistic. A 2-tail P<0.05 was considered statistically
significant. Statistical analysis was performed using R version
3.6.2 (R Core Team, 2019).

RESULTS
Patient Characteristics
A total of 71 patients with optimal preprocedural CT
scans were included in this study. Of these, 9 patients
developed LVOTO after the ViMAC procedure. The mean
age was greater in the group that developed LVOTO
(80.9 years versus 71.4 years; P=0.06). Hundred percent of patients who developed LVOTO were female
compared with 61.3% in the group who did not develop
LVOTO (P=0.02). The number of patients with a prior
aortic valve replacement was similar between both
groups (P=0.4). There were numerically more patients
in the group with LVOTO who had prior TAVR compared
to the group without LVOTO (P=0.02). New York Heart
Association class (P=0.79) and Society of Thoracic Surgery score (21.1 versus 14.4; P=0.08) were similar in
both groups (Table 1).

Echocardiographic Characteristics
Patients in both groups had similar baseline LVOT
systolic gradients (15.0 versus 4.1; P=0.08), ejection fraction (64.1 versus 61.4%; P=0.4), mean baseline mitral gradients (10.9 versus 12.4; P=0.4), and
severe tricuspid regurgitation (12.5% versus 17.1%;
P=0.75; Table 1).

Predictors of LVOTO in ViMAC

Table 1.

Baseline Demographics
No LVOT
obstruction;
N=62

LVOT
obstruction;
n=9

P value

Age, y

71.4±13.4

80.9±12.1

0.06

Female

38/62 (61.3%)

9/9 (100%)

0.02

Diabetes

25/54 (46.3%)

04/8 (50.0%)

0.85

Hypertension

44/55 (80.0%)

8/8 (100%)

0.16

Atrial fibrillation

22/51 (43.1%)

05/9 (55.6%)

0.49

Peripheral artery disease

9/54 (16.7%)

01/7 (14.3%)

0.87

COPD

19/54 (35.2%)

05/8 (62.5%)

0.14

CKD

31/56 (55.4%)

06/9 (66.7%)

0.53

CVA

10/54 (18.5%)

04/8 (50.0%)

0.05

Prior CABG

23/56 (41.1%)

02/9 (22.2%)

0.28

Prior PCI

8/42 (19.0%)

01/7 (14.3%)

0.76

Prior AVR

35/59 (59.3%)

04/9 (44.4%)

0.40

TAVR

7/35 (20%)

3/4 (75%)

0.02

SAVR

28/35 (80%)

1/4 (25%)

  Mechanical

11/27 (40.7%)

1/1 (100%)

  Bioprosthesis

16/27 (59.3%)

0/1 (0%)

Prior pacemaker

19/53 (35.8%)

03/8 (37.5%)

0.93

Hospit-n due to heart failure
within 12 mo

39/51 (76.5%)

7/8 (87.5%)

0.48

STS score

14.4±10.2

21.1±10.5

0.08

II

5/58 (8.6%)

1/9 (11.1%)

III

25/58 (43.1%)

4/9 (44.4%)

IV

28/58 (48.3%)

4/9 (44.4%)

  None

76/55 (10.9%)

1/8 (12.5%)

  Trace

7/55 (12.7%)

4/8 (50.0%)

  Mild

21/55 (38.2%)

1/8 (12.5%)

  Moderate

11/55 (20.0%)

2/8 (25.0%)

  Severe

10/55 (18.2%)

0/8 (0.0%)

Mitral valve area, cm

1.16±0.50

1.26±0.49

0.60

LVEF

61.1±10.0

64.1±6.6

0.40

 Peak LVOT mean systolic
gradient, median (IQR)

4.1±5.3

15.0±21.2

0.08

 Mean mitral valve diastolic gradient

12.4±4.9

10.9±2.8

0.40

Severe TR

07/41 (17.1%)

1/8 (12.5%)

0.75

RV dysfunction

13/42 (31.0%)

3/8 (37.5%)

0.72

NYHA functional class

0.24

0.79

Echocardiographic data
Mitral regurgitation

Procedural Data
There was no difference in the valve type, size, and
access between the 2 groups (Table 2).

MDCT Parameters
Mitral annular diastolic dimensions were similar
between both groups. Average MAC thickness (8.4
versus 8.3 mm; P=0.93), maximum MAC thickness
(11.8 versus 12.8 mm; P=0.59) and CT-based MAC
score were similar between both groups (7.9±0.8 versus 7.7±1.5; P=0.72). The mean length of the anterior mitral leaflet was shorter in the group with LVOTO
(18.6 versus 22.4 mm; P=0.02).
The mean LVOT area in systole was lower in the
group with LVOTO (331.1 versus 451.9 mm2; P=0.03).
Similarly, the neo-LVOT (145.3 versus 270.9; P=0.006)
and the indexed neo-LVOT (90.1 versus 157.4;
P=0.05) were also lower in the group with LVOTO, and
the expected % LVOT area reduction was higher in this
group (58.3 versus 42.7%; P=0.008). The VTS was
lower in the group with LVOTO (3.1 versus 6.9 mm;
P=0.002; Table 3).

2

0.12

AVR indicates aortic valve replacement; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease;
CVA, cerebrovascular accident; Hospit-n, hospitalization; IQR, interquartile range;
LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; NYHA,
New York Heart Association; PCI, percutaneous coronary intervention; RV, right
ventricular; SAVR, surgical aortic valve replacement; STS, Society of Thoracic Surgery; TAVR, transcatheter aortic valve replacement; and TR, tricuspid regurgitation.

Predictors of LVOT Obstruction
In univariable analysis, LVOT obstruction was associated with the LVOT area (R2=0.14; P=0.03), neo-LVOT
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Table 2. Procedural Outcomes
No LVOT
obstruction;
n=62

LVOT
obstruction;
n=9

P value

SAPIEN

05/62 (8.1%)

0/9 (0%)

0.38

SAPIEN XT

27/62 (43.5%)

5/9 (55.6%)

0.50

SAPIEN S3

29/62 (46.8%)

4/9 (44.4%)

0.90

Inovare

01/62 (1.6%)

0/9 (0%)

0.70

23

05/62 (8.1%)

2/9 (22.2%)

0.18

26

26/62 (41.9%)

3/9 (33.3%)

0.62

29

30/62 (48.4%)

4/9 (44.4%)

0.83

30 (Inovare)

01/62 (1.6%)

0/9 (0%)

0.70

Transapical

29/62 (46.8%)

5/9 (55.6%)

0.62

Transseptal

0.83; sensitivity, 0.68; specificity, 1; and accuracy, 0.73),
and the expected % LVOT area reduction cutoff was
63.5% (AUC, 0.80; sensitivity, 0.72; specificity, 0.68; and
accuracy, 0.68).

Device type

Device size

Access

29/62 (46.8%)

3/9 (33.3%)

0.45

 Transseptal wire
externalized via LV

04/62 (6.5%)

1/9 (11.1%)

0.61

AVR during procedure

0.54

4/61 (14.4%)

1/8 (11.1%)

TAVR

4/4 (0%)

1/1 (100%)

SAVR

0/4 (100%)

0/1 (0%)

Technical success*

48/62 (77.4%)

2/9 (22.2%)

<0.001

In-hospital death

10/62 (16.1%)

6/9 (66.7%)

<0.001

Conversion to open
heart surgery

04/58 (6.9%)

0/9 (0%)

0.44

Residual ≥3+MR

01/62 (1.6%)

0/9 (0%)

0.70

Need for second valve

10/62 (16.1%)

3/9 (33.3%)

0.21

Hemolytic anemia

01/57 (1.8%)

0/9 (0%)

0.69

Post-mean MVG

3.8±1.7

3.5±5.0

0.90

AVR indicates aortic valve replacement; LV, left ventricle; LVOT, left ventricular
outflow tract; MR, mitral regurgitation; MVARC, Mitral Valve Academic Research
Consortium; MVG, mean valve gradient; SAVR, surgical aortic valve replacement;
and TAVR, transcatheter aortic valve replacement.
*Technical success was defined according to the MVARC criteria.

area (R2=0.18; P=0.02), neo-LVOT area index (R2=0.15;
P=0.07), and VTS distance (R2=0.22; P=0.008). There
was inverse correlation between estimated neo-LVOT area
and the VTS and the measured peak LVOT gradient after
implantation of the THV. The small sample size and few
events prevented the conducting of a multivariable analysis.

Discriminatory Values of LVOT Obstruction
Predictors
The value of several MDCT variables in predicting LVOTO
were evaluated (Figure 2). The optimal discriminatory
cutoff valve for VTS was 5.5 mm (area under the curve
[AUC], 0.86; sensitivity, 0.72; specificity, 0.68; and accuracy, 0.68), whereas the cutoff for neo-LVOT area was
173.4 mm2 (AUC, 0.86; sensitivity, 0.8; specificity, 0.87;
and accuracy, 0.81), mean LVOT area was 371.5 mm2
(AUC, 0.76; sensitivity, 0.67; specificity, 0.87; and accuracy, 0.54), indexed Neo-LVOT was 127.5 mm2/m2 (AUC,

DISCUSSION
This substudy from the TMVR in MAC Global Registry
evaluated predictors of LVOT obstruction after ViMAC.
The principal findings of this analysis are (1) female sex
was strongly associated with LVOTO; (2) LVOTO occurrence was independent of baseline echocardiographic
parameters included in this analysis, device choice, and
procedural approach; (3) neo-LVOT area and related
parameters including systolic mean LVOT area, indexed
neo-LVOT area, and expected % LVOT area reduction
were all associated with LVOTO; and (4) a new parameter-the VTS was also predictive of LVOTO (Figure 3).
LVOTO remains an Achilles heel of ViMAC. In the
TMVR in MAC Global Registry, 13 (11.2%) patients with
severe MAC undergoing TMVR using balloon-expandable transcatheter aortic valves developed LVOTO. In
that study, LVOTO was a strong predictor of 30-day and
1-year mortality, despite salvage attempts including kissing balloon valvuloplasty, emergent surgery, and emergent alcohol septal ablation.4 Prediction of LVOTO risk as
part of procedural planning is therefore fundamental to
avoid this catastrophic complication.
LVOT area after ViMAC is determined by the interaction of the basal left ventricular septum, aortic valve,
anterior mitral valve leaflet, and transcatheter valve
frame.14 Patients with MAC often have a hypertrophic
basal septum, due to comorbidities such as hypertension and chronic kidney disease.15,16 Displacement of
the anterior mitral leaflet during valve deployment, along
with direct valve frame interaction, can further narrow the
LVOT.17 The most commonly used parameter to determine the risk of LVOTO during TMVR has been the neoLVOT area.13,14 Neo-LVOT area is determined by inserting
a virtual transcatheter valve in the mitral position on
MDCT using dedicated software, followed by tracing the
LVOT area delineated by the interventricular septum and
virtual valve frame in cross-sectional view. A study by
Wang et al7 evaluated 38 patients who underwent TMVR
(9 ViMAC, 12 valve-in-ring, and 17 valve-in-valve). This
study showed that a neo-LVOT surface area of ≤189.4
mm2 was associated with LVOTO with 100% sensitivity
and 96.8% specificity. Moreover, in this study, preprocedural MDCT predictors before TMVR were validated
using postprocedural MDCT, showing excellent correlation (R2=0.8169; P<0.0001).7 A subsequent larger study
by Yoon et al8 included a cohort of 194 patients undergoing TMVR for valve-in-valve (n=107), valve-in-ring (50
patients), and ViMAC (37 patients). Twenty-six patients
in that study had LVOTO. The predictive value of several
echocardiographic and MDCT variables was evaluated,
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Table 3.

Preprocedural Multidetector Computed Tomographic Data
No LVOT obstruction;
n=62

LVOT obstruction;
n=9

P value

Septolateral diameter, mm (diastole)

22.0±3.6

21.3±1.2

0.60

Intercommisural diameter, mm (diastole)

31.6±4.2

30.1±4.3

0.35

Trigone to trigone distance diastole, mm
(diastole)

23.4±3.8

22.0±3.7

0.32

Average MAC thickness

8.3±2.3

8.4±2.2

0.93

Minimal MAC thickness (diastole)

4.7±1.5

4.8±1.3

0.94

Maximal MAC thickness (systole)

12.8±5.4

11.8±3.4

0.59

Caseous MAC

17/62 (27.4%)

3/9 (33.3%)

0.71

Continuous MAC

39/62 (62.9%)

6/9 (66.7%)

0.83

MAC distribution

0.54

<180

06/62 (9.7%)

180–270

17/62 (27.4%)

0/9 (0%)
2/9 (22.2%)

>270

39/62 (62.9%)

7/9 (77.8%)

MAC score

7.7±1.5

7.9±0.8

0.72

Anterior mitral valve calcification

55/62 (88.7%)

9/9 (100%)

0.29

Length of anterior MV leaflet in 3-chamber
view in diastole, mm

22.4±3.9

18.6±4.6

0.02

Maximum septum thickness 10–15 mm below
annulus (end-systolic), mm

15.6±2.9

16.5±2.8

0.45

Septal bulge (>15 mm)

27/62 (43.5%)

6/8 (75%)

0.27

Aortomitral angle

126.75±7.9

124.5±7.9

0.46

VTS

6.9±3.2

3.1±1.9

0.002

LVOT area systole, mm2

451.9±146.1

331.1±117

0.03

Neo-LVOT area systole

270.9±122.8

145.3±45.5

0.006

Indexed neo-LVOT area systole

157.4±78.1

90.1±26.9

0.05

23 S3 (TA)

1/62 (1.6%)

0/9 (0%)

0.35

23 XT (TA)

1/62 (1.6%)

2/9 (22.2%)

23 S3 (TS)

2/62 (3.2%)

1/9 (11.1%)

26 XT (TA)

8/62 (12.9%)

1/9 (11.1%)

26 XT (TS)

5/62 (8.1%)

1/9 (11.1%)

26 S3 (TA)

2/62 (3.2%)

0/9 (0%)

26 S3 (TS)

4/62 (6.5%)

0/9 (0%)

29 XT (TS)

5/62 (8.1%)

1/9 (11.1%)

29 S3 (TS)

9/62 (14.5%)

1/9 (11.1%)

29 S3 (TA)

7/62 (11.3%)

2/9 (22.2%)

29 XT (TA)

7/62 (11.3%)

0/9 (0%)

30 mm Inovare

1/62 (1.6%)

0/9 (0%)

42.7±15.2

58.3±12.9

Sapien size and type for neo-LVOT

Expected %LVOT area reduction

0.008

LVOT indicates left ventricular outflow tract; MAC indicates mitral annular calcification; TA, transapical; TS, transseptal; and
VTS, virtual transcatheter heart valve to septum distance.

with a satisfactory intraobserver and interobserver variability. For the overall cohort, a smaller neo-LVOT area
and indexed neo-LVOT area were associated with LVOT
obstruction, with cutoff values of 170 mm2 and 0.92
cm2/m2, respectively.8

Complimentary to the advancements in preprocedural, several procedural techniques have been developed to preemptively mitigate the risk of LVOTO during
TMVR. Such techniques include alcohol septal ablation
before TMVR,18 anterior leaflet laceration during TMVR
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Figure 2. Receiver-operating characteristic curves for multidetector row computed tomographic parameters to predict left
ventricular outflow tract (LVOT) obstruction (LVOTO) post-transcatheter mitral valve replacement in mitral annular calcification.
VTS indicates virtual transcatheter heart valve to septum distance.

(LAMPOON technique),19 adoption of more invasive
transatrial approach with anterior leaflet resection or septal myectomy during TMVR,20 and radiofrequency ablation
of the basal ventricular septum.21 A recent single-center
study evaluated the outcomes of TMVR in patients with

MAC and failed ring repairs using all these techniques to
mitigate the risk of LVOTO. They found that despite the
advancements, the risk of LVOTO was still high at 13%.22
A major limitation of all previous studies has been the
heterogeneity of the population studied. These studies

Figure 3. Multidetector computed tomography analysis using 3Mensio Structural Heart Workflow (version 10.0, Pie Medical
Imaging, Maastricht, the Netherlands), showing neo–left ventricular outflow tract (LVOT) and virtual transcatheter heart valve to
septum distance (VTS) in low LVOT obstruction risk (LVOTO; left) and high LVOT obstruction (right).
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have included patients undergoing valve-in-valve, valvein-ring, and ViMAC procedures. These are very different procedures with different anatomic considerations;
as such, extrapolating the results of these studies to
each procedure separately may be limited. This study
assessed the risk of LVOTO specific to ViMAC. The core
lab adjudication of the MDCT’s is a major strength of
this study. The neo-LVOT area was significantly associated with LVOTO with a cutoff value of 173.4 mm2 (AUC,
0.86; sensitivity, 0.8; specificity, 0.87). Given that the neoLVOT area integrates baseline LVOT area with the virtual
valve frame, the association between systolic mean LVOT
area, indexed neo-LVOT area, and expected % LVOT area
reduction and LVOTO was not surprising. These findings
corroborate data from the prior studies. The lack of independent association of the septal bulge diameter and
anterior leaflet length with LVOTO supports the notion
that the latter is determined by the complex anatomic
interactions rather than individual anatomic parameters.
The association of the VTS with LVOTO at a cutoff of 5.5
mm was a novel finding. This measurement can be more
rapidly and predictably obtained compare to the neoLVOT area. Due to this, it may have a role in screening
those at high risk of LVOTO before TMVR.
Using these findings on MDCT would allow for a comprehensive risk assessment for LVOTO in patients undergoing ViMAC. This is particularly important for female
patients because female sex was shown in this analysis
to be associated with the risk of LVOTO. The low incidence of LVOTO in the current study may limit the predictive power of the cutoff values identified in this study.
Larger and more definitive studies are needed for further
validation of these findings.

Predictors of LVOTO in ViMAC

and validate the predictive performance of the cutoff
values reported in this study.
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